Endothelial function after anthracycline treatment.

Endothelial function after anthracycline treatment. - Endothelial Function after AnthraCycline Treatment (EFACT)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46659

Enrollment

Registered

2018-08-15

Start date

2019-02-21

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial dysfunction

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Female - Age >=18 years - Histological proven breast cancer - Planned treatment: a chemotherapeutic regimen containing anthracyclines.

Exclusion criteria

Exclusion criteria: Patients who are unable to fasten 3 hours prior to the measurement - Prior treatment with chemotherapy which contained anthracyclines, platinum derivates or bleomycin. - Prior treatment with high dose chest radiation (i.e. >20Gy) - Possible confounders on endothelial function o Current smokers and patients who quitted smoking

Design outcomes

Primary

Measure	Time frame
Endothelial function is measured by reactive hyperemia index (RHI) with a peripheral arterial tonometry (PAT).	—

Secondary

Measure	Time frame
Demographics, cardiovascular risk factors, medical history, oncological treatment protocol will be obtained from the patient file which is used at the outpatient clinic.	—

Countries

Netherlands

Outcome results